Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
Neuroleptic malignant syndrome in a patient with COVID-19 and the possible role of SARS-CoV-2 in its manifestation. Case report and overview of published cases (preprint)
researchsquare; 2024.
Preprint
en Inglés
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-3985519.v1
ABSTRACT
Background:
The manifestationof severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is more complex than that of pulmonary infection, and neuropsychiatric symptoms play a role in this complexity. In this paper, we present the case of a 29-year-old schizophrenic patient who suffered from neuroleptic malignant syndrome (NMS) that developed during coronavirus disease 2019 (COVID-19) infection, with an emphasis on the possible connection between these two conditions. Additionally, we provide an overview of published NMS cases in patients with COVID-19 or after vaccination against SARS-CoV-2. Case presentation A 29-year-old patient treated for schizophrenia was admitted to the hospital for agitation and aggressivity; shortly after arrival at the hospital, laryngospasm and hypoxia occurred. The patient tested positive for SARS-CoV-2, and later, he developed pneumonia. After continuing restlessness, haloperidol was administered, and a few days later, neuroleptic malignant syndrome occurred. He was treated with bromocriptine and recovered.Conclusions:
As SARS-CoV-2 is known to interact with angiotensin-converting enzyme 2 and DOPA-decarboxylase is known to be coexpressed with this receptor, we hypothesized that COVID-19 infection might playa substantial role in the development of NMS.
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
PREPRINT-RESEARCHSQUARE
Asunto principal:
Neumonía
/
Agitación Psicomotora
/
Embolia Pulmonar
/
Esquizofrenia
/
Laringismo
/
Infecciones por Coronavirus
/
COVID-19
/
Hipoxia
/
Trastornos Mentales
/
Síndrome Neuroléptico Maligno
Idioma:
Inglés
Año:
2024
Tipo del documento:
Preprint
Similares
MEDLINE
...
LILACS
LIS